Clinical Trials Logo

Lung Neuroendocrine Neoplasm clinical trials

View clinical trials related to Lung Neuroendocrine Neoplasm.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05064150 Enrolling by invitation - Clinical trials for Neuroendocrine Tumors

Neuroendocrine Tumors - Patient Reported Outcomes

NET-PRO
Start date: May 10, 2022
Phase:
Study type: Observational

With so many therapeutic options available (i.e.: biologic therapy, liver directed therapy, radiotherapy and chemotherapy), the purpose of this project is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiveness and sequencing of therapy for neuroendocrine tumors (NET) patients. We will conduct a study of all newly occurring GEP-NET and lung NET cases aged 18 years and older diagnosed between 01/01/2018 through 12/31/2023 across 14 sites participating in the National Patient-Centered Clinical Research Network (PCORnet), enrolling an average of 215 patients per site over the 3 year study period (~3,000 patients total), allowing up to 60 months of follow-up for medical record outcomes. Participants will complete four online or paper surveys over 18 months; these surveys will focus on patient-reported outcomes, including questions on quality of life, treatment decisions, and experiences with cancer care. Survey data will be linked to participant medical record data to achieve study aims.